The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells

Oncotarget

Volumn 5, Issue 21, 2014, Pages 10678-10691

  Ringer, Lymor ^a   Sirajuddin, Paul ^a   Tricoli, Lucas ^a   Waye, Sarah ^a   Choudhry, Muhammad Umer ^a   Parasido, Erika ^a   Sivakumar, Angiela ^a   Heckler, Mary ^a   Naeem, Aisha ^a   Abdelgawad, Iman ^a,f   Liu, Xuefeng ^b   Feldman, Adam S ^c   Lee, Richard J ^c   Wu, Chin Lee ^c   Yenugonda, Venkata ^a   Kallakury, Bhaskar ^b   Dritschilo, Anatoly ^d   Lynch, John ^d   Schlegel, Richard ^a,b   Rodriguez, Olga ^a   Pestell, Richard G ^e   Avantaggiati, Maria Laura ^a   Albanese, Chris ^a,b   more..

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f NATIONAL CANCER INSTITUTE   (Egypt)

Author keywords

Apoptosis; Autophagy; P53; Primary cells; Prostate

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; PURVALANOL B; UNCLASSIFIED DRUG; VMY 1 103; 2-CHLORO-N-(2-(5-(DIMETHYLAMINO)NAPHTHALENE-1-SULFONAMIDO)ETHYL)-4-(2-(1-HYDROXY-3-METHYLBUTAN-2-YLAMINO)-9-ISOPROPYL-9H-PURIN-6-YLAMINO)BENZAMIDE; ADENINE; DANSYL CHLORIDE; TP53 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL; CELL DEATH; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; G2 PHASE CELL CYCLE CHECKPOINT; GENOTYPE; HUMAN; HUMAN CELL; MISSENSE MUTATION; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTON TRANSPORT; ANALOGS AND DERIVATIVES; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; MALE; METABOLISM; MUTATION; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENINE; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CELL PROLIFERATION; DANSYL COMPOUNDS; FLOW CYTOMETRY; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84916940406     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2528     Document Type: Article

References (51)

1. de Bruin EC and Medema JP. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev. 2008; 34(8):737-749.
2. Guerriero JL, Ditsworth D, Fan Y, Zhao F, Crawford HC and Zong WX. Chemotherapy induces tumor clearance independent of apoptosis. Cancer Res. 2008; 68(23):9595-9600.
3. Galluzzi L, Vitale I, Vacchelli E and Kroemer G. Cell death signaling and anticancer therapy. Front Oncol. 2011; 1:5.
4. Hou W, Zhang Q, Yan Z, Chen R, Zeh Iii HJ, Kang R, Lotze MT and Tang D. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis. 2013; 4:e966.
5. Levine B and Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008; 132(1):27-42.
6. Levine B and Kroemer G. Autophagy in aging, disease and death: the true identity of a cell death impostor. Cell Death Differ. 2009; 16(1):1-2.
7. Choi AM, Ryter SW and Levine B. Autophagy in human health and disease. N Engl J Med. 2013; 368(7):651-662.
8. Guo JY, Xia B and White E. Autophagy-mediated tumor promotion. Cell. 2013; 155(6):1216-1219.
9. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W, Teng X, Snyder E, Santanam U, Dipaola RS, Jacks T, Rabinowitz JD and White E. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 2013; 27(13):1447-1461.
10. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H and Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999; 402(6762):672-676.
11. Liu EY and Ryan KM. Autophagy and cancer-issues we need to digest. J Cell Sci. 2012; 125(Pt 10):2349-2358.
12. Lamy L, Ngo VN, Emre NC, Shaffer AL, 3rd, Yang Y, Tian E, Nair V, Kruhlak MJ, Zingone A, Landgren O and Staudt LM. Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell. 2013; 23(4):435-449.
13. Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, Reynoso K, Bargonetti J, Wellstein A, Albanese C and Avantaggiati ML. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle. 2013; 11(23):4436-4446.
14. Catalina-Rodriguez O, Kolukula VK, Tomita Y, Preet A, Palmieri F, Wellstein A, Byers S, Giaccia AJ, Glasgow E, Albanese C and Avantaggiati ML. The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget. 2012; 3(10):1220-1235.
15. Muller PA and Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014; 25(3):304-317.
16. Tasdemir E, Chiara Maiuri M, Morselli E, Criollo A, D'Amelio M, Djavaheri-Mergny M, Cecconi F, Tavernarakis N and Kroemer G. A dual role of p53 in the control of autophagy. Autophagy. 2008; 4(6):810-814.
17. Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, Cai Y, Norberg HV, Zhang T, Furuya T, Jin M, Zhu Z, Wang H, Yu J, Li Y, Hao Y, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011; 147(1):223-234.
18. Vousden KH and Ryan KM. p53 and metabolism. Nat Rev Cancer. 2009; 9(10):691-700.
19. Nikoletopoulou V, Markaki M, Palikaras K and Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta. 2013; 1833(12):3448-3459.
20. Choudhury S, Kolukula VK, Preet A, Albanese C and Avantaggiati ML. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? Cell Cycle. 2013; 12(7):1022-1029.
21. GarufiA, Pucci D, D'Orazi V, Cirone M, Bossi G, Avantaggiati ML and D'Orazi G. Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell Death Dis. 2014; 5:e1271.
22. Chapman S, Liu X, Meyers C, Schlegel R and McBride AA. Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor. J Clin Invest. 2010; 120(7):2619-2626.
23. Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, Timofeeva O, Nealon C, Dalic A, Simic V, Haddad B, Rhim J, Dritschilo A, Riegel A, McBride A and Schlegel R. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. American Journal of Pathology. 2012; 180(2):590-607.
24. Yuan H, Myers S, Wang J, Zhou D, Woo JA, Kallakury B, Ju A, Bazylewicz M, Carter YM, Albanese C, Grant N, Shad A, Dritschilo A, Liu X and Schlegel R. Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N Engl J Med. 2012; 367(13):1220-1227.
25. Palechor-Ceron N, Suprynowicz FA, Upadhyay G, Dakic A, Minas T, Simic V, Johnson M, Albanese C, Schlegel R and Liu X. Radiation Induces Diffusible Feeder Cell Factor(s) That Cooperate with ROCK Inhibitor to Conditionally Reprogram and Immortalize Epithelial Cells. Am J Pathol. 2013; 183(6):1862-1870.
26. Ringer L, Yenugonda VM, Ghosh A, Divito K, Trabosh V, Patel Y, Brophy A, Grindrod S, Lisanti MP, Rosenthal D, Brown ML, Avantaggiati ML, Rodriguez O and Albanese C. VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biol Ther. 2010; 10(4):320-325.
27. Ringer L, Sirajuddin P, Heckler M, Ghosh A, Suprynowicz F, Yenugonda VM, Brown ML, Toretsky JA, Uren A, Lee Y, MacDonald TJ, Rodriguez O, Glazer RI, Schlegel R and Albanese C. VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biol Ther. 2011; 12(9):818-826.
28. Smahi A, Courtois G, Vabres P, Yamaoka S, Solange H, Munnich A, Israël A, Heiss NS, Klauck SKP and Wiemann Sea. Genomic rearrangment in NEMO impairs NF-κB activation and is a cause of incontinentia pigmenti (IP). Nature. 2000; 405:466-472.
29. Sirajuddin P, Das S, Ringer L, Rodriguez O, Sivakumar A, Lee Y, Uren A, Fricke S, Rood B, Ozcan A, Wang SS, Karam S, Yenugonda VM, Salinas P, Petricoin EF, 3rd, Lisanti MP, et al. Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. Cell Cycle. 2012; 11(20):3801-3809.
30. Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G and Erbersdobler A. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol. 2008; 21(11):1371-1378.
31. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991; 51(23 Pt 1):6304-6311.
32. Yenugonda VM, Deb TB, Grindrod SC, Dakshanamurthy S, Yang Y, Paige M and Brown ML. Fluorescent cyclindependent kinase inhibitors block the proliferation of human breast cancer cells. Bioorg Med Chem. 2011; 19(8):2714-2725.
33. Kolukula VK, Sahu G, Wellstein A, Rodriguez OC, Preet A, Iacobazzi V, D'Orazi G, Albanese C, Palmieri F and Avantaggiati ML. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker. Oncotarget. 2014.
34. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J, Fersht AR, Hainaut P, Wiman KG and Bykov VJ. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009; 15(5):376-388.
35. Kang R, Zeh HJ, Lotze MT and Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011; 18(4):571-580.
36. Schwartz-Roberts JL, Shajahan AN, Cook KL, Warri A, Abu-Asab M and Clarke R. GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther. 2013; 12(4):448-459.
37. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2009; 19(1):107-120.
38. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012; 8(4):445-544.
39. Lee C, Kim JS and Waldman T. Activated PI3K signaling as an endogenous inducer of p53 in human cancer. Cell Cycle. 2007; 6(4):394-396.
40. Suprynowicz FA, Upadhyay G, Krawczyk E, Kramer SC, Hebert JD, Liu X, Yuan H, Cheluvaraju C, Clapp PW, Boucher RC, Jr., Kamonjoh CM, Randell SH and Schlegel R. Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proc Natl Acad Sci U S A. 2012; 109(49):20035-20040.
41. Pollock CB, McDonough S, Wang VS, Lee H, Ringer L, Li X, Prandi C, Lee RJ, Feldman AS, Koltai H, Kapulnik Y, Rodriguez OC, Schlegel R, Albanese C and Yarden RI. Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogramed primary prostate cancer cells. Oncotarget. 2014.
42. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012; 19(1):107-120.
43. Booth LA, Tavallai S, Hamed HA, Cruickshanks N and Dent P. The role of cell signalling in the crosstalk between autophagy and apoptosis. Cell Signal. 2013.
44. Fimia GM, Corazzari M, Antonioli M and Piacentini M. Ambra1 at the crossroad between autophagy and cell death. Oncogene. 2013; 32(28):3311-3318.
45. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C and Pan H. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013; 4:e838.
46. Jing K, Song KS, Shin S, Kim N, Jeong S, Oh HR, Park JH, Seo KS, Heo JY, Han J, Park JI, Han C, Wu T, Kweon GR, Park SK, Yoon WH, et al. Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53. Autophagy. 2011; 7(11):1348-1358.
47. Hyman A and Simons K. The New Cell Biology: Beyond HeLa Cells. Nature. 2011; 480(7375):34.
48. Begley CG and Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012; 483(7391):531-533.
49. Albanese C, D'Amico M, Reutens AT, Fu M, Watanabe G, Lee RJ, Kitsis RN, Henglein B, Avantaggiati M, Somasundaram K, Thimmapaya B and Pestell RG. Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem. 1999; 274:34186-34195.
50. Albanese C, Wu K, D'Amico M, Jarrett C, Joyce D, Hughes J, Hulit J, Sakamaki T, Fu M, Ben-Ze'ev A, Bromberg JF, Lamberti C, Verma U, Gaynor RB, Byers SW and Pestell RG. IKKalpha Regulates Mitogenic Signaling through Transcriptional Induction of Cyclin D1 via Tcf. Mol Biol Cell. 2003; 14(2):585-599.
51. Perez RE, Knights CD, Sahu G, Catania J, Kolukula VK, Stoler D, Graessmann A, Ogryzko V, Pishvaian M, Albanese C and Avantaggiati ML. Restoration of DNAbinding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. J Cell Physiol. 2010; 225(2):394-405.